TY - JOUR
T1 - Quantitative analysis of cabozantinib in pharmaceutical dosage forms using green RP-HPTLC and green NP-HPTLC methods
T2 - A comparative evaluation
AU - Alam, Prawez
AU - Salem-Bekhit, Mounir M.
AU - Al-Joufi, Fakhria A.
AU - Alqarni, Mohammed H.
AU - Shakeel, Faiyaz
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/6
Y1 - 2021/6
N2 - In this study, a novel antitumor drug cabozantinib (CZN) was estimated by a validated green reversed-phase high-performance thin-layer chromatography (RP-HPTLC) and normal-phase high-performance thin-layer chromatography (NP-HPTLC) techniques in the marketed tablets and capsules. The RP-HPTLC densitometry analysis of CZN was carried out using “RP-18 silica gel 60 F254S HPTLC plates”. Green acetone/water (85:15, v v−1) combination was applied as the mobile phase for a RP-HPTLC-densitometry. However, green NP-HPTLC analysis of CZN was conducted using “NP-18 silica gel 60 F254S HPTLC plates”. Green ethyl acetate/ethanol (97.5:2.5, v v−1) combination was applied for a green NP-HPLTC-densitometry. The detection of CZN was performed at λmax = 247 nm for both of the techniques. The RP-HPTLC technique showed high sensitivity for the quantification of CZN in comparison to NP-HPTLC-densitometry. For a green RP-HPTLC-densitometry, the CZN content of marketed tablets and capsules were found to be 101.17% and 98.77%, respectively. However, for a green NP-HPTLC-densitometry, the CZN content of the marketed tablets and capsules were found to be 96.12% and 94.25%, respectively. Accordingly, the green RP-HPTLC technique was identified better than a green NP-HPTLC technique. Hence, the RP-HPTLC-densitometry can be successfully used for the quantification of CZN in pharmaceutical dosage forms containing CZN as one of the constituents.
AB - In this study, a novel antitumor drug cabozantinib (CZN) was estimated by a validated green reversed-phase high-performance thin-layer chromatography (RP-HPTLC) and normal-phase high-performance thin-layer chromatography (NP-HPTLC) techniques in the marketed tablets and capsules. The RP-HPTLC densitometry analysis of CZN was carried out using “RP-18 silica gel 60 F254S HPTLC plates”. Green acetone/water (85:15, v v−1) combination was applied as the mobile phase for a RP-HPTLC-densitometry. However, green NP-HPTLC analysis of CZN was conducted using “NP-18 silica gel 60 F254S HPTLC plates”. Green ethyl acetate/ethanol (97.5:2.5, v v−1) combination was applied for a green NP-HPLTC-densitometry. The detection of CZN was performed at λmax = 247 nm for both of the techniques. The RP-HPTLC technique showed high sensitivity for the quantification of CZN in comparison to NP-HPTLC-densitometry. For a green RP-HPTLC-densitometry, the CZN content of marketed tablets and capsules were found to be 101.17% and 98.77%, respectively. However, for a green NP-HPTLC-densitometry, the CZN content of the marketed tablets and capsules were found to be 96.12% and 94.25%, respectively. Accordingly, the green RP-HPTLC technique was identified better than a green NP-HPTLC technique. Hence, the RP-HPTLC-densitometry can be successfully used for the quantification of CZN in pharmaceutical dosage forms containing CZN as one of the constituents.
KW - Cabozantinib
KW - Normal-phase HPTLC
KW - Reversed-phase HPTLC
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=85101591887&partnerID=8YFLogxK
U2 - 10.1016/j.scp.2021.100413
DO - 10.1016/j.scp.2021.100413
M3 - Article
AN - SCOPUS:85101591887
SN - 2352-5541
VL - 21
JO - Sustainable Chemistry and Pharmacy
JF - Sustainable Chemistry and Pharmacy
M1 - 100413
ER -